US76155X1000 - Common Stock
REVOLUTION MEDICINES INC
NASDAQ:RVMD (3/28/2024, 8:00:02 PM)
After market: 32.23 0 (0%)32.23
+0.51 (+1.61%)
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 338 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The Company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (RASG12D) are in clinical development. Additional RAS(ON) Inhibitors in the Company’s pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C) which are in IND-enabling development, and additional compounds targeting other RAS variants. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers at all three of the major mutation hotspot positions, G12, G13, and Q61. EQRx, Inc. is the Company’s wholly owned subsidiary.
REVOLUTION MEDICINES INC
700 Saginaw Dr
Redwood City CALIFORNIA 94063
P: 14157663638
CEO: Mark A. Goldsmith
Employees: 338
Website: https://www.revmed.com/
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...
Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time...
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel...
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...
Here you can normally see the latest stock twits on RVMD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: